{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:54:21Z","timestamp":1788310461058,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ejmech.2020.112255","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T12:19:45Z","timestamp":1584706785000},"page":"112255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Design, synthesis, in\u00a0vitro and in silico studies of novel 4-oxoquinoline ribonucleoside derivatives as HIV-1 reverse transcriptase inhibitors"],"prefix":"10.1016","volume":"194","author":[{"given":"Luana da S.M.","family":"Forezi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana M.J.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andressa","family":"Marttorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana L.","family":"Abrantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos R.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Carla","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago Moreno L.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda da C.S.","family":"Boechat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra M.T.","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cec\u00edlia B.V.","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112255_bib1","author":"UNAIDS - United"},{"key":"10.1016\/j.ejmech.2020.112255_bib2","author":"WHO - World Health Organization"},{"issue":"10","key":"10.1016\/j.ejmech.2020.112255_bib3","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1089\/vim.2017.0065","article-title":"Mechanisms and factors that drive extensive human immunodeficiency virus type-1 hypervariability: an overview","volume":"30","author":"Yaseen","year":"2017","journal-title":"Viral Immunol."},{"key":"10.1016\/j.ejmech.2020.112255_bib4","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1039\/C5RA25722K","article-title":"Advances in the development of pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors","volume":"6","author":"Vite-Caritino","year":"2016","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.ejmech.2020.112255_bib5","first-page":"e1328","article-title":"Integrative approaches in HIV-1 non-nucleoside reverse transcriptase inhibitor design","volume":"8","author":"Poongavanam","year":"2017","journal-title":"Wiley Interdiscip. Rev.: Comput. Mol. Sci."},{"key":"10.1016\/j.ejmech.2020.112255_bib6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejmech.2019.04.054","article-title":"Recent progress in HIV-1 inhibitors targeting the entrance channel of HIV-1 non-nucleoside reverse transcriptase inhibitor binding pocket","volume":"174","author":"Gu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2020.112255_bib7","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2217\/fmb.15.106","article-title":"Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection","volume":"10","author":"Sluis-Cremer","year":"2015","journal-title":"Future Microbiol."},{"issue":"3","key":"10.1016\/j.ejmech.2020.112255_bib8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/157016208784324930","article-title":"The compound 6-Chloro-1,4-Dihydro-4-Oxo-1-(\u03b2-D-Ribofuranosyl) quinoline-3-carboxylic acid inhibits HIV-1 replication by targeting the enzyme reverse transcriptase","volume":"6","author":"Souza","year":"2008","journal-title":"Curr. HIV Res."},{"issue":"3","key":"10.1016\/j.ejmech.2020.112255_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/157016209788347958","article-title":"Characterization of HIV-1 enzyme reverse transcriptase inhibition by the compound 6-chloro-1,4-dihydro-4-oxo-1-(beta-D-ribofuranosyl) quinoline-3-carboxylic acid through kinetic and in silico studies","volume":"7","author":"Souza","year":"2009","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.ejmech.2020.112255_bib10","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.1016\/j.bmc.2009.06.037","article-title":"Synthesis, antiviral activity and molecular modeling of oxoquinoline derivatives","volume":"17","author":"Santos","year":"2009","journal-title":"Bioorg. Med. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2020.112255_bib11","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"Automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2020.112255_bib12","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1073\/pnas.94.8.3984","article-title":"Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor","volume":"94","author":"Esnouf","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2020.112255_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jpba.2017.02.012","article-title":"Identification, characterization and in silico ADMET prediction of Roflumilast degradation products","volume":"138","author":"Pinheiro","year":"2017","journal-title":"J.\u00a0Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2020.112255_bib14","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1021\/ja01265a088","article-title":"The synthesis of certain substituted quinolines and 5,6-benzoquinolines","volume":"61","author":"Gould","year":"1939","journal-title":"J.\u00a0Am. Chem. Soc."},{"issue":"3","key":"10.1016\/j.ejmech.2020.112255_bib15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/(SICI)1098-1071(1999)10:3<197::AID-HC4>3.0.CO;2-Z","article-title":"Synthesis of novel nucleosides of 4-oxoquinoline-3-carboxylic acid analogues","volume":"10","author":"Matta","year":"1999","journal-title":"Heteroat. Chem."},{"key":"10.1016\/j.ejmech.2020.112255_bib16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1081\/NCN-120016510","article-title":"Synthesis and antiviral evaluation of isatin ribonucleosides","volume":"21","author":"Oliveira","year":"2002","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"issue":"3","key":"10.1016\/j.ejmech.2020.112255_bib17","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1590\/S0103-50532002000300012","article-title":"An efficient and short route for the synthesis of reverse pyrrole ribonucleosides","volume":"13","author":"Pereira","year":"2002","journal-title":"J.\u00a0Braz. Chem. Soc."},{"issue":"6","key":"10.1016\/j.ejmech.2020.112255_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3851\/IMP1607","article-title":"Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors","volume":"20","author":"La Regina","year":"2010","journal-title":"Antivir. Chem. Chemother."},{"issue":"2","key":"10.1016\/j.ejmech.2020.112255_bib19","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1021\/ci200454v","article-title":"Combining global and local measures for structure-based druggability predictions","volume":"52","author":"Volkamer","year":"2012","journal-title":"J.\u00a0Chem. Inf. Model."},{"issue":"10","key":"10.1016\/j.ejmech.2020.112255_bib20","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2174\/13816128113199990295","article-title":"Anti-HIV drug development: structural features and limitations of present day drugs and future challenges in the successful HIV\/AIDS treatment","volume":"19","author":"Kumari","year":"2013","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.ejmech.2020.112255_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-198917010-00001","article-title":"Clinical pharmacokinetics of zidovudine. An overview of current data","volume":"17","author":"Collins","year":"1989","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2020.112255_bib22","series-title":"Sande\u2019s HIV\/AIDS Medicine","first-page":"133","article-title":"Overview of antiretroviral therapy","author":"Coffey","year":"2012"},{"issue":"7","key":"10.1016\/j.ejmech.2020.112255_bib23","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1124\/dmd.108.024851","article-title":"Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4","volume":"37","author":"Wen","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"1\u20133","key":"10.1016\/j.ejmech.2020.112255_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF01435004","article-title":"The toxicity of azidothymidine (AZT) on human and animal cells in culture at concentrations used for antiviral therapy","volume":"95","author":"Chiu","year":"1995","journal-title":"Genetica"},{"key":"10.1016\/j.ejmech.2020.112255_bib25","first-page":"1","article-title":"NTP toxicology and carcinogenesis studies of AZT (CAS No. 30516-87-1) and AZT\/alpha-Interferon A\/D B6C3F1 mice (gavage studies)","volume":"469","author":"National Toxicology Program","year":"1999","journal-title":"Natl. Toxicol. Progr. Tech. Rep."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420302221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420302221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:09:16Z","timestamp":1759327756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420302221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":25,"alternative-id":["S0223523420302221"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112255","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, in\u00a0vitro and in silico studies of novel 4-oxoquinoline ribonucleoside derivatives as HIV-1 reverse transcriptase inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112255"}}